LCAM
GLUE icon

Long Corridor Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Long Corridor Asset Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40,000
Closed -$278K – 23
2024
Q4 		$278K Hold
40,000
– – 0.21% 16
2024
Q3 		$212K Hold
40,000
– – 0.19% 17
2024
Q2 		$150K Hold
40,000
– – 0.14% 20
2024
Q1 		$282K Buy
+40,000
New +$237K 0.25% 12

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Long Corridor Asset Management's GLUE Position: Q1 2025 in Review

Long Corridor Asset Management sold out of Monte Rosa Therapeutics (GLUE) in Q1 2025, closing a stake of 40,000 shares — an estimated $278K sold.

Long Corridor Asset Management first reported a position in GLUE in Q1 2024 and held it in 4 quarters. The position peaked at $282K in Q1 2024. 105 funds tracked by Wall St. Rank hold GLUE as of Q1 2025.

  • Long Corridor Asset Management reported no remaining Monte Rosa Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Long Corridor Asset Management sold 40,000 Monte Rosa Therapeutics shares in Q1 2025, an estimated $278K.
  • Long Corridor Asset Management first reported a position in Monte Rosa Therapeutics in Q1 2024 and held it in 4 quarters.
  • Long Corridor Asset Management's Monte Rosa Therapeutics position peaked at $282K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2025.

Based on Long Corridor Asset Management's 13F filing for Q1 2025, filed 13 May 2025.